Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KiSS: Levetiracetam for Sepsis-Associated Encephalopathy
NCT06851078Phase 3Not yet recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Mar 2025
- Primary completion
- Jun 2027
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in sepsis-associated encephalopathy (SAE) comparing Early Levetiracetam administration with Placebo control (2 arms). Primary endpoint: Number of days alive without delirium or coma at 14 days. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
levetiracetam
03
Conditions
sepsis-associated encephalopathy (SAE)
Beyond the preview
Go deeper on NCT06851078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06851078.